UPDATE ON THE FINANCIAL SITUATION
PROGRESS OF THE RESTRUCTURING PLAN
Houdeng-Goegnies (Belgium), March 7, 2023, 6:00 p.m. – As part of its major transformation plan, Pharmasimple (ISIN Code: BE0974302342. Ticker: ALPHS) is continuing its policy of transparency towards the financial community and provides below the necessary information on the evolution of its debt reduction and on the restructuring measures in progress.
Compared to 31/12/2022, the debt situation has evolved as follows:
|
In €m (unaudited data) |
02/28/2023 |
31/12/2022 |
Variation |
Reminder 31/12/2021 |
|
Equity |
2.0 | 3.8 | -47% |
4.1 |
|
Treasury |
0.4 | 0.6 | -39% |
1.1 |
|
Long term bank debt |
0.9 | 0.9 | – |
5.5 |
|
Short term bank debt |
0.5 | 0.5 | -15% |
4.2 |
|
Payables |
2.4 |
2.8 |
-14% |
3.6 |
As of February 28, 2023, Pharmasimple’s net debt amounted to €1.0 million, to which is added €2.4 million in trade payables. The cumulative total of the two debt items shows a reduction of €0.2 million in two months, the result of the active policy of reducing supplier outstandings inherited from the divested Internet activity.
The mechanical reduction in shareholders’ equity is linked to returns from pharmacies, whose acquisition Pharmasimple has decided to postpone. To date, the company operates 6 pharmacies in Belgium.
The reorganization of structural staff has continued since 1
er
January with the departure of 5 employees, reducing the administrative staff from 11 to 6.
Pharmasimple intends to continue its debt reduction efforts in 2023, in order to return to a financial structure compatible with its new economic model, centered on the operation of pharmacies, and with its forecast level of activity.
The company also wishes to find alternative and/or complementary financing solutions to convertible bonds in order to resume its ambitious program of pharmacy acquisitions, while limiting the dilution of its capital.
Warning for investors: Pharmasimple has been using financing in the form of convertible bonds since April 2022, which includes risks of strong downward pressure on the share price and high dilution due to the large number of securities issued.
contacts:
Company
Pharmasimple
Michael Willems
Financial communication
Cap Value
About Pharmasimple
:
About Pharmasimple: Pharmasimple is a distribution group specializing in the sale of pharmaceutical and parapharmaceutical products. With a network of around ten pharmacies in Belgium, the company aims to become one of the leaders in its sector in this country through an ambitious program of external growth. In 2021, Pharmasimple achieved sales of €30.0 million. Pharmasimple shares are listed on the Euronext Growth market. ISIN code: BE0974302342. Mnemonic: ALPHS.
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lW9tZsluYmmdlp9tZJ2Wl2Nll5iSxWeVZ5PJlGeZZZzFb5ppm22Wl5ycZnBpnWhv
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/78839-cp-pharmasimple-point-situation-financiere-au-28022023-vdef.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com